Description
The advancement and innovation of new healthcare technologies are developing the platform for the growth of precision medicine market. Since, the announcement of ?Precision Medicine Initiative? by the president Barack Obama in January end ,2015, a large number of research and development has been taken for the development of precise drugs, targeted therapeutics, and laboratory tests. Presently, the main focus of the government initiatives is toward oncology, but it is anticipated to target almost all therapeutic area affected by genetic mutations.
Government regulations and standards are sustaining the growth and development of the precision medicine market. The main aim of these regulations is to make the precision medicines more adaptable and focused toward genetic diseases related to Oncology, skin, respiratory, CNS, CVD, and infectious diseases among others. The patients are benefitted indirectly by these regulations as it save time and cut-down cost as the patients get the required treatment for the specific disease.
The precision medicine market growth is propelled by increasing demand for personalized treatment, technological innovation and advancement (Biomarker-based tests/kits, next gene sequencing, and precise imaging), Government support and regulations have created a demand for the precision medicine solutions.
Our study includes an overview and analysis of the precision medicine market by ecosystem, sub-markets, therapeutics and geographical regions, allowing the research to develop a comprehensive outlook of the market. The precision medicine market report presents detailed analysis of the entire precision medicine ecosystem and provides extensive insights of the different developments, trends and key participants. The report also focuses on different sub-markets which help in the development of precision medicine solutions. The sub-market verticals are categorized into five major categories, viz. companion diagnostics, biomarkers, targeted therapeutics, Pharmacogenomics and molecular diagnostics among others in the report.
Further, the scope of the report includes the therapeutics of different disease types managed by this technology. All of the above mentioned report coverage parameters are discussed across different regions like The Americas, Europe, Asia Pacific (APAC) and Rest of the World (ROW).
While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliance, and regulatory bodies and their involvement in the precision medicine market.
The answers to the following key questions can be found in the report:
? What are the major market drivers, challenges and opportunities of the precision medicine market and their use cases?
? What are the precision medicine market trends and key developments for different precision medicine systems?
? What are the key developmental strategies in different applications across all regions?
? What are different types of precision medicine solutions and the latest precision medicine technologies?
? How will the key market players leverage on key developments such as Mergers and Acquisitions, Partnerships, and Product Launch among others?
? Which geographical region will lead the global precision medicine market by the end of the forecast period?
? Who are the key players in the precision medicine market?
? What are the government regulations for different precision medicine solutions?
? What are different types of sub-markets in precision medicine market and what are the applications in which they are being used?
? What is the different used case scenarios considered under different applications?
? What are the different therapeutic applications in which precision medicine products are being used?
? What are the precision medicine market trends and key developments in different geographical regions?
The research tries to answer various aspects of the precision medicine market such as factors driving the market, its threats that can possibly slow down the market growth and the current growth opportunities that are going to shape the market expansion of precision medicine solutions. The research incorporates Porter?s Five Force Model for in-depth analysis of the precision medicine market and an assessment of the factors governing it. The report builds itself upon a comprehensive value chain giving a clear understanding of ecosystem of precision medicine market penetration.
Towards the end of the report, readers will have a clear understanding of the market dynamics, major drivers and the underlying threats and challenges that the global precision medicine industry is subjected to, including the estimation of the industry?s growth in terms of production and revenue.
The report includes the profiles of major players in the precision medicine market that allows its reader to get an insight into the industry trends.
Table of contents
Executive Summary
1 REPORT SCOPE 26
1.1 SCOPE OF THE STUDY 26
1.2 PRECISION MEDICINE: REPORT COVERAGE 27
1.3 BIS RESEARCH METHODOLOGY 29
1.3.1 RESEARCH METHODOLOGY FOR THE GLOBAL MARKET STUDY 30
1.3.1.1 Geographical Analysis 30
1.3.1.2 Demand Side & Supply Side Analysis 31
1.3.1.3 Data Synthesis and Bridging 31
1.3.2 GLOBAL PRECISION MEDICINE: RESEARCH METHODOLOGY 32
1.3.3 KEY DATA POINT SOURCES 33
1.3.3.1 Data Points taken from Secondary Sources 33
1.3.3.2 Data Points taken from Primary Sources 33
1.4 REPORT DESCRIPTION 34
2 EXECUTIVE SUMMARY 38
3 MARKET OVERVIEW 42
3.1 INTRODUCTION 42
3.2 MARKET TIMELINE 42
3.3 KEY PARTICIPANTS, STRATEGIES & DEVELOPMENTS 50
3.3.1 GOVERNMENT AGENCIES 50
3.3.2 ACADEMIC INSTITUTIONS 50
3.3.3 DEVICE & SERVICE PROVIDERS 51
3.4 KEY MARKET STRATEGIES AND DEVELOPMENTS 51
3.4.1 INTRODUCTION 51
3.4.2 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS 52
3.4.3 MERGERS & ACQUISITIONS 54
3.4.4 PRODUCT DEVELOPMENT AND LAUNCH 56
3.4.5 BUSINESS EXPANSION/CONTRACTS 57
3.4.6 PATENTS, APPROVALS AND CERTIFICATIONS 59
3.4.7 OTHERS (EVENTS & RECOGNITIONS) 60
4 MARKET DYNAMICS 61
4.1 INTRODUCTION 61
4.2 MARKET DRIVERS 62
4.2.1 PATIENTS INVOLVEMENT IN PERSONAL HEALTHCARE 62
4.2.2 TECHNOLOGIES DRIVING THE MARKET (E.G. NEXT-GENERATION SEQUENCING TECHNOLOGIES, ULTRA-HIGH THROUGHPUT SEQUENCING) 64
4.2.3 INCREASE IN GENETIC DISEASES 64
4.2.4 POTENTIAL FOR MORE TARGETED THERAPIES 65
4.2.5 INTEGRATION OF BIG DATA HEALTHCARE COMPANIES WITH PHARMA & BIOTECH COMPANIES 65
4.3 MARKET CHALLENGES 66
4.3.1 POTENTIAL THREAT TO PERSONAL DATA 66
4.3.2 HIGH DIAGNOSTIC COST AS A BARRIER 67
4.3.3 POTENTIAL RISK OF HARDWARE OR SOFTWARE FAILURE 68
4.3.4 STRINGENT REGULATIONS AND STANDARDS 68
4.3.5 LACK OF AWARENESS ABOUT THE POSSIBLE APPLICATIONS OF PRECISION MEDICINE 70
4.3.6 REIMBURSEMENT POLICIES AND REGULATORY FRAMEWORK 71
4.3.7 LIMITED KNOWLEDGE ABOUT THE APPLICATION OF TEST AND TECHNIQUES 71
4.3.8 LACK OF RESEARCH AND EVIDENCES CREATING HINDRANCES IN ITS APPLICATION 72
4.4 MARKET OPPORTUNITIES 73
4.4.1 INTRODUCTION OF PRECISION MEDICINE SOLUTIONS IN DEVELOPING ECONOMIES 73
4.4.2 DOWNSIZING THE COST OF GENOME SEQUENCING TO THREE DIGITS 74
5 INDUSTRY DYNAMICS 76
5.1 VALUE CHAIN ANALYSIS 76
5.1.1 DEVICE MANUFACTURER & DRUG PRODUCERS 77
5.1.2 HEALTHCARE PROVIDERS 77
5.1.3 HEALTHCARE ITS OR BIG DATA COMPANIES 77
5.1.4 REGULATORS 77
5.1.5 THIRD PARTY PAYERS 78
5.1.6 PATIENTS 78
5.2 PORTER FIVE FORCE ANALYSIS 78
5.2.1 BARGAINING POWER OF BUYER (PATIENT) 79
5.2.2 BARGAINING POWER OF SUPPLIER 80
5.2.3 THREAT FROM SUBSTITUTE 82
5.2.4 THREAT FROM A NEW ENTRANT 83
5.2.5 INTENSITY OF COMPETITIVE RIVALRY 84
6 CONSORTIUMS, CERTIFICATION, REGULATIONS, AND STANDARDS 85
6.1 INTRODUCTION 85
6.1.1 REGULATORY BODIES 86
6.1.1.1 Food and Drug Administration (FDA) 89
6.1.1.2 Medicines and Healthcare products Regulatory Agency (MHRA) 91
6.1.1.3 Therapeutic Goods Administration (TGA)-Australia 91
6.1.1.4 Conformit? Europ?enne (CE) 92
6.1.2 CONSORTIUMS 92
6.1.3 ALLIANCES/ASSOCIATIONS 94
7 GLOBAL PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS 96
7.1 INTRODUCTION 96
7.1.1 MARKET STATISTICS 97
7.2 PHARMACEUTICALS AND BIOTECHNOLOGY COMPANIES 99
7.2.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 105
7.2.1.1 Market Trends 105
7.2.1.2 Market Developments 105
7.2.1.3 Key Participants 106
7.3 DIAGNOSTIC COMPANIES 107
7.3.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 111
7.3.1.1 Market Trends 111
7.3.1.2 Market Developments 112
7.3.1.3 Key Participants 112
7.4 HEALTHCARE IT SPECIALISTS/ BIG DATA COMPANIES 113
7.4.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 119
7.4.1.1 Market Trends 119
7.4.1.2 Market Developments 120
7.4.1.3 Key Participants 121
7.5 CLINICAL LABORATORIES 121
7.5.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 125
7.5.1.1 Regulatory bodies and compliances 125
7.5.1.2 Market Trends 126
7.5.1.3 Key Participants 127
8 GLOBAL PRECISION MEDICINE MARKET BY SUB-MARKETS 128
8.1 INTRODUCTION 128
8.1.1 MARKET STATISTICS 129
8.2 COMPANION DIAGNOSTICS 131
8.3 BIOMARKER-BASED TEST 135
8.3.1 ROLE OF BIOBANKING INTO BIOMARKER 137
8.3.2 KEY PARTICIPANTS 141
8.4 TARGETED THERAPEUTICS 142
8.4.1 KEY PARTICIPANTS 144
8.5 PHARMACOGENOMICS (PGX) 144
8.5.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 149
8.5.1.1 Market Trends 149
8.5.1.2 Market Developments 150
8.5.1.3 Key Participants 151
8.6 MOLECULAR DIAGNOSTICS 151
8.7 OTHERS 157
8.7.1 NEXT-GENERATION SEQUENCING 159
8.7.2 CONSUMER GENOMICS 159
8.7.2.1 Key Participants 159
8.7.3 3D PRINTING 160
8.7.4 PROSTHETICS MARKET 160
8.7.5 HUMAN TISSUES MARKET 160
9 GLOBAL PRECISION MEDICINE MARKET BY THERAPEUTICS 162
9.1 INTRODUCTION 162
9.1.1 MARKET STATISTICS 163
9.2 CANCER/ONCOLOGY 164
9.2.1 MARKET STATISTICS 165
9.2.2 TYPES OF CANCER 167
9.2.3 DRUGS & TESTS 170
9.2.4 KEY MARKET TRENDS, DEVELOPMENTS & PARTICIPANTS 172
9.2.4.1 Market Trends 172
9.2.4.2 Market Developments 172
9.2.4.3 Key Participants 174
9.3 CARDIOVASCULAR DISEASE (CVD) 175
9.3.1 MARKET STATISTICS 176
9.3.2 DRUGS & TESTS 179
9.3.3 MARKET TRENDS & MARKET DEVELOPMENTS 180
9.3.3.1 Market trend 180
9.3.3.2 Market Developments 181
9.3.3.3 Key Participants 181
9.4 CENTRAL NERVOUS SYSTEM 182
9.4.1 MARKET STATISTICS 182
9.4.2 NEUROLOGICAL 184
9.4.2.1 Neurological Drugs & Tests 185
9.4.3 PSYCHIATRIC DISORDERS 186
9.4.3.1 Psychiatric Disorder Drugs & Tests 186
9.4.4 MARKET TENDS & MARKET DEVELOPMENTS 188
9.4.4.1 Market Trends 188
9.4.4.2 Key Developments 188
9.4.4.3 Key Participants 188
9.5 INFECTIOUS DISEASES 189
9.5.1 MARKET STATISTICS 189
9.5.2 INFECTIOUS DISEASES DRUGS & TESTS 192
9.5.3 MARKET DEVELOPMENTS & PARTICIPANTS 193
9.5.3.1 Key Developments 193
9.5.3.2 Key Participants 194
9.6 OTHERS 194
9.6.1 MARKET STATISTICS 195
9.6.2 MARKET TRENDS, DEVELOPMENTS & PARTICIPANTS 200
9.6.2.1 Market Trends 200
9.6.2.2 Key Developments 200
9.6.2.3 Key Participants 201
10 GLOBAL PRECISION MEDICINE MARKET BY GEOGRAPHY 202
10.1 INTRODUCTION 202
10.1.1 MARKET STATISTICS 203
10.2 THE AMERICAS 204
10.2.1 NORTH AMERICA 207
10.2.1.1 The U.S. 208
10.2.1.2 Canada 209
10.2.1.3 Others 210
10.2.1.4 Key Market Trends, Developments and Participants 210
10.2.1.5 Regulations and Compliances 210
10.2.1.6 Market Trends 210
10.2.1.7 Market Developments 211
10.2.1.8 Key Participants 211
10.2.2 SOUTH AMERICA 212
10.2.2.1 Key Market Trends, Developments and Participants 212
10.2.2.2 Regulations and Compliances 212
10.2.2.3 Market Trends 212
10.2.2.4 Key Participants 212
10.3 EUROPE 213
10.3.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 216
10.3.1.1 Regulations and Compliances 216
10.3.1.2 Market Developments 216
10.3.1.3 Key Participants 218
10.4 ASIA-PACIFIC (APAC) 218
10.4.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 222
10.4.1.1 Market Developments 222
10.4.1.2 Key Participants 223
10.5 REST OF THE WORLD/MIDDE EAST & AFRICA (MEA) 223
10.5.1 AFRICA 225
10.5.1.1 Middle East 226
10.5.2 KEY MARKET DEVELOPMENTS AND PARTICIPANTS 226
10.5.2.1 Market Developments 226
10.5.2.2 Key Participants 226
11 COMPANY PROFILES 227
11.1 ABBOTT LABORATORIES 227
11.1.1 OVERVIEW 227
11.1.2 FINANCIALS 228
11.1.2.1 Overall Financials 228
11.1.2.2 Financials by Segment 228
11.1.2.3 Financials by Region 229
11.1.2.4 Key Developments 229
11.1.3 SWOT ANALYSIS 231
11.2 ALMAC GROUP, LTD. 232
11.2.1 OVERVIEW 232
11.2.2 FINANCIALS 232
11.2.3 KEY DEVELOPMENTS 233
11.2.4 SWOT ANALYSIS 234
11.3 ASURAGEN, INC. 235
11.3.1 OVERVIEW 235
11.3.2 FINANCIALS 235
11.3.3 KEY DEVELOPMENTS 236
11.3.4 SWOT ANALYSIS 237
11.4 BIOM?RIEUX SA 238
11.4.1 OVERVIEW 238
11.4.2 FINANCIALS 239
11.4.2.1 Overall Financials 239
11.4.2.2 Financials By Region 239
11.4.2.3 Financials By Segment 240
11.4.3 KEY DEVELOPMENTS 240
11.4.4 SWOT ANALYSIS 242
11.5 CEPHEID INC. 243
11.5.1 OVERVIEW 243
11.5.2 FINANCIALS 244
11.5.2.1 Overall Financials 244
11.5.2.2 Net Revenue By Segment 245
11.5.2.3 Net Revenue By Region 245
11.5.3 KEY DEVELOPMENTS 246
11.5.4 SWOT ANALYSIS 247
11.6 CETICS HEALTHCARE TECHNOLOGIES GMBH 248
11.6.1 OVERVIEW 248
11.6.2 FINANCIALS 248
11.6.3 KEY DEVELOPMENTS 249
11.6.4 SWOT ANALYSIS 250
11.7 GE HEALTHCARE 251
11.7.1 OVERVIEW 251
11.7.2 FINANCIALS 252
11.7.2.1 Overall Financials 252
11.7.2.2 Net Revenue By Segment 253
11.7.2.3 Financial Summary 254
11.7.3 KEY DEVELOPMENTS 254
11.8 GLAXOSMITHKLINE PLC (GSK) 256
11.8.1 OVERVIEW 256
11.8.2 FINANCIALS 257
11.8.2.1 Overall Financials 257
11.8.2.2 Financials By Segment 257
11.8.2.3 Financials By Region 258
11.8.2.4 Financials By Therapeutics 258
11.9 INTOMICS A/S 259
11.9.1 OVERVIEW 259
11.9.2 FINANCIALS 259
11.9.3 KEY DEVELOPMENTS 259
11.9.4 SWOT ANALYSIS 260
11.10 JOHNSON & JOHNSON 261
11.10.1 OVERVIEW 261
11.10.2 FINANCIALS 262
11.10.2.1 Overall Financials 262
11.10.2.2 Net Revenue By Segment 262
11.10.2.3 Net revenue by Region 263
11.10.3 KEY DEVELOPMENTS 263
11.11 LABORATORY CORPORATION OF AMERICA HOLDINGS 264
11.11.1 OVERVIEW 264
11.11.2 FINANCIALS 265
11.11.2.1 Overall Financials 265
11.11.2.2 Financials by Segment 266
11.11.3 KEY DEVELOPMENTS 266
11.11.4 SWOT ANALYSIS 268
11.12 MEDTRONIC 269
11.12.1 OVERVIEW 269
11.12.2 FINANCIALS 270
11.12.2.1 Overall Financials 270
11.12.3 KEY DEVELOPMENTS 270
11.13 NOVARTIS 272
11.13.1 OVERVIEW 272
11.13.2 FINANCIALS 273
11.13.2.1 Overall Financials 273
11.13.2.2 Financials By Region 274
11.13.2.3 Financials By Segment 274
11.14 PFIZER INC. 275
11.14.1 OVERVIEW 275
11.14.2 FINANCIALS 276
11.14.2.1 Overall Financials 276
11.14.2.2 Net Revenue By Segment 276
11.14.2.3 Net Revenue By Region 277
11.14.3 KEY DEVELOPMENTS 277
11.14.4 SWOT ANALYSIS 279
11.15 QIAGEN 280
11.15.1 OVERVIEW 280
11.16 BIOBASE GMBH (SUBSIDIARY) 281
11.16.1 OVERVIEW 281
11.16.2 FINANCIALS 282
11.16.2.1 Overall Financials 282
11.16.3 KEY DEVELOPMENTS (BIOBASE) 283
11.17 QUEST DIAGNOSTICS INC 284
11.17.1 OVERVIEW 284
11.17.2 FINANCIALS 285
11.17.2.1 Overall Financials 285
11.17.2.2 Net Revenue By Segment 286
11.17.3 KEY DEVELOPMENTS 286
11.17.4 SWOT ANALYSIS 288
11.18 RANDOX LABORATORIES LTD. 289
11.18.1 OVERVIEW 289
11.18.2 FINANCIALS 289
11.18.3 KEY DEVELOPMENTS 290
11.18.4 SWOT ANALYSIS 291
11.19 ROCHE HOLDING AG-BR 292
11.19.1 OVERVIEW 292
11.19.2 FINANCIALS 293
11.19.2.1 Overall Financials 293
11.19.2.2 Net Revenue By Segment 293
11.19.3 KEY DEVELOPMENTS 294
11.19.4 SWOT ANALYSIS 295
11.20 SANOFI PHARMA 296
11.20.1 OVERVIEW 296
11.20.2 FINANCIALS 297
11.20.2.1 Overall Financials 297
11.20.2.2 Net Revenue By Segment 297
11.21 TAKEDA PHARMACEUTICAL COMPANY LIMITED 298
11.21.1 OVERVIEW 298
11.21.2 FINANCIALS 299
11.21.2.1 Overall Financials 299
11.21.3 KEY DEVELOPMENTS 299
11.21.4 SWOT ANALYSIS 301
11.22 TEVA PHARMACEUTICAL INDUSTRIES LTD. 302
11.22.1 OVERVIEW 302
11.22.2 FINANCIALS 303
11.22.2.1 Overall Financials 303
11.22.2.2 Net Revenue By Segment 303
11.22.2.3 Net Revenue By Segment 304
11.22.3 KEY DEVELOPMENTS 304
11.22.4 SWOT ANALYSIS 307
11.23 AB-BIOTICS SA 308
11.23.1 OVERVIEW 308
11.24 CARIS LIFE SCIENCES 309
11.24.1 OVERVIEW 309
11.25 HEALTHCORE, INC. 310
11.25.1 OVERVIEW 310
11.26 IBM 311
11.26.1 OVERVIEW 311
11.27 INNVENTIS 312
11.27.1 OVERVIEW 312
11.28 INTEL CORPORATION 313
11.28.1 OVERVIEW 313
11.29 MOLECULAR HEALTH GMBH 314
11.29.1 OVERVIEW 314
11.30 PRECISION FOR MEDICINE 315
11.30.1 OVERVIEW 315LIST OF TABLES
TABLE 1 LEADING COMPANIES IN THE PRECISION MEDICINE MARKET 37
TABLE 2 DOWNSIZING COST OF GENOME SEQUENCING 74
TABLE 3 FACTORS IMPACTING THE BUYER?S BARGAINING POWER 80
TABLE 4 FACTORS IMPACTING THE SUPPLIER?S BARGAINING POWER 81
TABLE 5 FACTORS IMPACTING THE THREAT FROM SUBSTITUTE 82
TABLE 6 FACTORS IMPACTING THE THREAT FROM NEW ENTRANT 83
TABLE 7 FACTORS IMPACTING THE DEGREE OF COMPETITION 84
TABLE 8 REGULATORY BODIES IN PRECISION MEDICINE MARKET 87
TABLE 9 CONSORTIUMS IN PRECISION MEDICINE MARKET 93
TABLE 10 ALLIANCES/ASSOCIATIONSIN PRECISION MEDICINE MARKET 94
TABLE 11 GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION) 97
TABLE 12 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION) 100
TABLE 13 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION) 101
TABLE 14 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION) 102
TABLE 15 KEY DEVELOPMENTS IN PHARMA & BIOTECH COMPANIES(2015) 105
TABLE 16 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION) 107
TABLE 17 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION) 108
TABLE 18 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION) 109
TABLE 19 KEY DEVELOPMENTS IN DIAGNOSTIC COMPANIES(2015) 112
TABLE 20 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION) 113
TABLE 21 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION) 114
TABLE 22 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION) 115
TABLE 23 KEY DEVELOPMENTS IN HEALTHCARE IT/BIG DATA COMPANIES(2015) 120
TABLE 24 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION) 122
TABLE 25 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION) 123
TABLE 26 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION) 124
TABLE 27 GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION) 129
TABLE 28 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 131
TABLE 29 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION) 132
TABLE 30 LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES 133
TABLE 31 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 135
TABLE 32 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION) 136
TABLE 33 LIST OF BIOBANKS 138
TABLE 34 EXAMPLES OF BIOBANKING INITIATIVES ACROSS SELECTED OECD COUNTRIES 139
TABLE 35 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 142
TABLE 36 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION) 143
TABLE 37 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 145
TABLE 38 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION) 146
TABLE 39 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 152
TABLE 40 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION) 153
TABLE 41 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM
